Molecular therapies for HCC: Looking outside the box von Faivre, Sandrine, Rimassa, Lorenza, Finn, Richard S.

Volltext

Evolution of Systemic Therapy for Hepatocellular Carcinoma von Finn, Richard S., Zhu, Andrew X.

Volltext

The Role of Angiogenesis in Hepatocellular Carcinoma von Morse, Michael A, Sun, Weijing, Kim, Richard, He, Aiwu Ruth, Abada, Paolo B, Mynderse, Michelle, Finn, Richard S

Volltext

Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases von Marrero, Jorge A., Kulik, Laura M., Sirlin, Claude B., Zhu, Andrew X., Finn, Richard S., Abecassis, Michael M., Roberts, Lewis R., Heimbach, Julie K.

Volltext

Hepatocellular Carcinoma: Pick the Winner-Tyrosine Kinase Inhibitor Versus Immuno-oncology Agent-Based Combinations von Bejjani, Anthony C, Finn, Richard S

Volltext

Palbociclib and Letrozole in Advanced Breast Cancer von Finn, Richard S, Martin, Miguel, Rugo, Hope S, Jones, Stephen, Im, Seock-Ah, Gelmon, Karen, Harbeck, Nadia, Lipatov, Oleg N, Walshe, Janice M, Moulder, Stacy, Gauthier, Eric, Lu, Dongrui R, Randolph, Sophia, Diéras, Véronique, Slamon, Dennis J

Volltext

Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference von Llovet, Josep M., Villanueva, Augusto, Marrero, Jorge A., Schwartz, Myron, Meyer, Tim, Galle, Peter R., Lencioni, Riccardo, Greten, Tim F., Kudo, Masatoshi, Mandrekar, Sumithra J., Zhu, Andrew X., Finn, Richard S., Roberts, Lewis R.

Volltext

Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond von Raoul, Jean-Luc, Kudo, Masatoshi, Finn, Richard S., Edeline, Julien, Reig, Maria, Galle, Peter R.

Volltext

Development of Molecularly Targeted Therapies in Hepatocellular Carcinoma: Where Do We Go Now? von Finn, Richard S

Volltext

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, ad... von Finn, Richard S, MD, Crown, John P, Prof, Lang, Istvan, MD, Boer, Katalin, MD, Bondarenko, Igor M, Prof, Kulyk, Sergey O, MD, Ettl, Johannes, MD, Patel, Ravindranath, MD, Pinter, Tamas, MD, Schmidt, Marcus, MD, Shparyk, Yaroslav, MD, Thummala, Anu R, MD, Voytko, Nataliya L, MD, Fowst, Camilla, MD, Huang, Xin, PhD, Kim, Sindy T, BS, Randolph, Sophia, MD, Slamon, Dennis J, Prof

Volltext

Identification of a Therapeutic Strategy Targeting Amplified FGF19 in Liver Cancer by Oncogenomic Screening von Sawey, Eric T., Chanrion, Maia, Cai, Chunlin, Wu, Guanming, Zhang, Jianping, Zender, Lars, Zhao, Alice, Busuttil, Ronald W., Yee, Herman, Stein, Lincoln, French, Dorothy M., Finn, Richard S., Lowe, Scott W., Powers, Scott

Volltext

Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2-metastatic breast cancer in US real-world clinical practice von DeMichele, Angela, Cristofanilli, Massimo, Brufsky, Adam, Liu, Xianchen, Mardekian, Jack, McRoy, Lynn, Layman, Rachel M., Emir, Birol, Torres, Mylin A., Rugo, Hope S., Finn, Richard S.

Volltext

SRC: A Century of Science Brought to the Clinic von Aleshin, Alexey, Finn, Richard S.

Volltext

Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study von LLOVET, Josep M, DECAENS, Thomas, MATHURIN, Philippe, FARTOUX, Laetitia, LIN, Deng-Yn, BRUIX, Jordi, POON, Ronnie T, SHERMAN, Morris, BLANC, Jean-Frédéric, FINN, Richard S, TAK, Won-Young, YEE CHAO, RAOUL, Jean-Luc, EZZEDDINE, Rana, LIU, David, WALTERS, Ian, PARK, Joong-Won, BOUCHER, Eveline, KUDO, Masatoshi, CHANG, Charissa, KANG, Yoon-Koo, ASSENAT, Eric, LIM, Ho-Yeong, BOIGE, Valerie

Volltext

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro von Finn, Richard S, Dering, Judy, Conklin, Dylan, Kalous, Ondrej, Cohen, David J, Desai, Amrita J, Ginther, Charles, Atefi, Mohammad, Chen, Isan, Fowst, Camilla, Los, Gerret, Slamon, Dennis J

Volltext

Combination immunotherapy for hepatocellular carcinoma von Rimassa, Lorenza, Finn, Richard S., Sangro, Bruno

Volltext

Radiofrequency ablation of hepatocellular carcinoma as bridge therapy to liver transplantation: A 10‐year intention‐to‐treat analysis von Lee, Min Woo, Raman, Steven S., Asvadi, Nazanin H., Siripongsakun, Surachate, Hicks, Robert M., Chen, Jeffrey, Worakitsitisatorn, Akeanong, McWilliams, Justin, Tong, Myron J., Finn, Richard S., Agopian, Vatche G., Busuttil, Ronald W., Lu, David S.K.

Volltext

Dasatinib as a Single Agent in Triple-Negative Breast Cancer: Results of an Open-Label Phase 2 Study von FINN, Richard S, BENGALA, Carmelo, IBRAHIM, Nuhad, ROCHE, Henri, SPARANO, Joseph, STRAUSS, Lewis C, FAIRCHILD, Justin, SY, Oumar, GOLDSTEIN, Lori J

Volltext

Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer:... von Ettl, Johannes, Im, Seock-Ah, Ro, Jungsil, Masuda, Norikazu, Colleoni, Marco, Schnell, Patrick, Bananis, Eustratios, Lu, Dongrui R., Cristofanilli, Massimo, Rugo, Hope S., Finn, Richard S.

Volltext

Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study von Kudo, Masatoshi, Finn, Richard S., Qin, Shukui, Han, Kwang-Hyub, Ikeda, Kenji, Cheng, Ann-Lii, Vogel, Arndt, Tovoli, Francesco, Ueshima, Kazuomi, Aikata, Hiroshi, López, Carlos López, Pracht, Marc, Meng, Zhiqiang, Daniele, Bruno, Park, Joong-Won, Palmer, Daniel, Tamai, Toshiyuki, Saito, Kenichi, Dutcus, Corina E., Lencioni, Riccardo

Volltext